Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Inactive
Last updated: May 7, 2026
Monthly Mifepristone
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): King George's Medical College
Inactive
Last updated: March 23, 2026
Emergency Oral Meloxicam
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Emergency
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): CONRAD, ICMER
Active
Last updated: March 18, 2026
Nanoparticle-Based Ethinylestradiol Patch
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Transdermal
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Veterinary and Animals Sciences Lahore, Mirpur University of Science and Technology
Active
Last updated: March 18, 2026
3D-Printed Lactic Acid + GML Intravaginal Ring
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): UNC Chapel Hill, North Carolina State University, CONRAD
Active
Last updated: January 22, 2026
Dual Prevention Pill
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Viatris, Population Council, AIDS Vaccine Advocacy Coalition (AVAC), HIV Prevention Trials Network
Active
Last updated: January 21, 2026
HELES Patch
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intradermal
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Lagos
Active
Last updated: January 14, 2026
AltaSeal
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Fallopian Tube
  • Intended Duration: Permanent
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): AltaScience
Active
Last updated: January 13, 2026
Acetic Acid Thermoreversible Gel
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): National Research Institute for Family Planning, China
Active
Last updated: January 13, 2026
Norelgestromin-Only Patch

MR-130A-01

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Transdermal
  • Intended Duration: Short-Acting
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Viatris